Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ NextDecade stock surges after TD Cowen upgrades to Buy (Investing.com) +++ NEXTDECADE Aktie +5,98%

VANDA Aktie

 >VANDA Aktienkurs 
3.84 EUR    -1.0%    (Tradegate)
Ask: 3.9 EUR / 3900 Stück
Bid: 3.84 EUR / 4000 Stück
Tagesumsatz: 200 Stück
Realtime Kurs von 8 bis 22 Uhr!
VANDA Aktie über LYNX handeln
>VANDA Performance
1 Woche: -2,3%
1 Monat: +2,4%
3 Monate: -15,1%
6 Monate: -13,6%
1 Jahr: -30,9%
laufendes Jahr: -15,5%
>VANDA Aktie
Name:  VANDA PHARMACEUTICALS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US9216591084 / A0JJT3
Symbol/ Ticker:  VM4 (Frankfurt) / VNDA (NASDAQ)
Kürzel:  FRA:VM4, ETR:VM4, VM4:GR, NASDAQ:VNDA
Index:  -
Webseite:  https://www.vandapharma.c..
Marktkapitalisierung:  237.1 Mio. EUR
Umsatz:  174.33 Mio. EUR
EBITDA:  -55.9 Mio. EUR
Gewinn je Aktie:  -0.571 EUR
Schulden:  10.16 Mio. EUR
Liquide Mittel:  295.16 Mio. EUR
Umsatz-/ Gewinnwachstum:  5.4% / -
KGV/ KGV lG:  - / 30.77
KUV/ KBV/ PEG:  1.31 / 0.52 / -
Gewinnm./ Eigenkapitalr.:  -21.98% / -8.39%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 32.130 USD.
Suchwörter:  VANDA
Letzte Datenerhebung:  24.06.25
>VANDA Eigentümer
Aktien: 58.93 Mio. St.
f.h. Aktien: 52.46 Mio. St.
Insider Eigner: 7.16%
Instit. Eigner: 77.63%
>VANDA Peer Group

 
17.06.25 - 11:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Vanda Pharmaceuticals im Wert von 32130 USD (Insiderkauf)
 
Mitchell, Stephen Ray - Aufsichtsrat - Tag der Transaktion: 2025-06-13...
27.05.25 - 15:01
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting (PR Newswire)
 
WASHINGTON, May 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, to be held in Scottsdale, Arizona, from May 27 through May 30, 2025. The following will be......
22.05.25 - 07:01
Insiderhandel: President and CEO kauft Aktien von Vanda Pharmaceuticals im Wert von 43996 USD (Insiderkauf)
 
Polymeropoulos, Mihael Hristos - Vorstand - Tag der Transaktion: 2025-05-21...
21.05.25 - 10:12
APP Group Introduces Sinar Vanda Hi-Brite: A Sustainable and High-Performance Paperboard Solution (PR Newswire)
 
JAKARTA, Indonesia, May 21, 2025 /PRNewswire/ -- Packaging serves as a crucial component across industries, safeguarding products during transit, minimizing contamination risks, and extending shelf life. As environmental awareness grows, businesses are adopting sustainable packaging to......
20.05.25 - 01:01
Insiderhandel: President and CEO kauft Aktien von Vanda Pharmaceuticals im Wert von 84472 USD (Insiderkauf)
 
Polymeropoulos, Mihael Hristos - Vorstand - Tag der Transaktion: 2025-05-16...
16.05.25 - 23:33
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 (PR Newswire)
 
WASHINGTON, May 16, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in investor meetings at the Mizuho Neuro & Ophthalmology Summit 2025 in New York City on Wednesday, May 21, 2025. About Vanda Pharmaceuticals Inc.......
08.05.25 - 02:00
Vanda pharmaceuticals outlines $210M-$250M revenue target for 2025 amid product launches (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
07.05.25 - 22:03
Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results (PR Newswire)
 
Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024 Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024 Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date......
05.05.25 - 14:01
Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026 (PR Newswire)
 
WASHINGTON, May 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) informed Vanda that the New Drug Application (NDA) for Bysanti™ (milsaperidone) has been filed, and that at this time no potential......
02.05.25 - 14:48
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 (PR Newswire)
 
Conference Call and Webcast to Follow WASHINGTON, May 2, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2025 on Wednesday, May 7, 2025, after the market closes. Vanda will host a conference call at 4:30......
23.04.25 - 23:00
Vanda claims FDA ′unlawfully′ delays hearing request on tradipitant decision (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
23.04.25 - 21:54
FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA (PR Newswire)
 
WASHINGTON, April 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced that FDA bureaucrats have committed to delay Vanda's request for a hearing on the approvability of tradipitant for gastroparesis. Rather than take accountability, FDA bureaucrats......
07.04.25 - 14:01
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting (PR Newswire)
 
WASHINGTON, April 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Academy of Neurology (AAN) Annual Meeting, to be held in San Diego, California from April 5 through April 9, 2025. The following will be presented:......
04.04.25 - 08:48
Oil Suffers; Trump Open to Tariff Negotiations | Horizons Middle East & Africa 04/04/2025 (Bloomberg)
 
Markets are still digesting Donald Trump's tariff announcements yesterday while the US President says he is open to something "phenomenal" in negotiations. Plus, OPEC+ unexpectedly announced an increase in supply by 3 times the planned amount in May sending the market into a spiral. Also on the show, President Trump's tariffs impact on some of Africa's poorest economies. And the future of TikTok in the US. Guests include: Mark Matthews, Julius Baer Head of Asia Research; Vandana Hari, VANDA Insights Founder; and Jordan Rochester, Mizuho Bank FICC Strategy Head (Source: Bloomberg)...
04.04.25 - 07:24
Hari: Oil Markets Still Digesting Trump′s Tariffs (Bloomberg)
 
Oil prices fell as President Trump's tariffs spurred demand fears and OPEC+'s decision to increase output faster than previously announced. Vandana Hari, Founder of VANDA Insights told Horizons Middle East and Africa anchor Joumanna Bercetche, rather than focusing on the increased output in May, she sees oil markets still looking out for President Trump's tariffs and potential negotiations. (Source: Bloomberg)...
31.03.25 - 14:06
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia (PR Newswire)
 
WASHINGTON, March 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) requesting marketing approval of Bysanti™ (milsaperidone) for the treatments of acute......
07.03.25 - 01:01
Insiderhandel: President and CEO kauft Aktien von Vanda Pharmaceuticals im Wert von 50150 USD (Insiderkauf)
 
Polymeropoulos, Mihael Hristos - Vorstand - Tag der Transaktion: 2025-03-06...
06.03.25 - 02:01
Insiderhandel: President and CEO kauft Aktien von Vanda Pharmaceuticals im Wert von 50200 USD (Insiderkauf)
 
Polymeropoulos, Mihael Hristos - Vorstand - Tag der Transaktion: 2025-03-05...
05.03.25 - 06:02
Insiderhandel: President and CEO kauft Aktien von Vanda Pharmaceuticals im Wert von 47050 USD (Insiderkauf)
 
Polymeropoulos, Mihael Hristos - Vorstand - Tag der Transaktion: 2025-03-03...
01.03.25 - 04:02
Insiderhandel: President and CEO kauft Aktien von Vanda Pharmaceuticals im Wert von 47600 USD (Insiderkauf)
 
Polymeropoulos, Mihael Hristos - Vorstand - Tag der Transaktion: 2025-02-28...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Was man zu lang bedenkt, das wird bedenklich. - Sprichwort
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!